Biomarkers of angiogenesis in twin gestations and the risk of preeclampsia — review of the current literature by Kozlowski, Szymon et al.
773
RE VIE W PAPER /  OBSTE TRICS
Ginekologia Polska
2020, vol. 91, no. 12, 773–776





Second Department of Obstetrics and Gynecology, Center of Postgraduate Medical Education, Warsaw, Poland
e-mail: katarzyna.kosinska-kaczynska@cmkp.edu.pl
Biomarkers of angiogenesis in twin gestations and the 
risk of preeclampsia — review of the current literature
Szymon Kozlowski1 , Magdalena Zgliczynska2 , Katarzyna Kosinska-Kaczynska2
1University Center for Woman and Newborn Health of the Medical University of Warsaw, Poland 
2Second Department of Obstetrics and Gynecology, Center of Postgraduate Medical Education, Warsaw, Poland
ABSTRACT
Twin pregnancy is one of the key risk factors for the development of preeclampsia.
Soluble fms-like tyrosine kinase-1, placental growth factor, and soluble endoglin are molecules involved in the process of 
angiogenesis with a proven role in the pathogenesis of preeclampsia. The aim of the review was to summarize available 
data on maternal serum levels of the biomarkers of angiogenesis and their usefulness in predicting preeclampsia in twin 
pregnancies. Most of available data suggest biomarkers concentrations differ between singleton and twin gestation and 
are related to chorionicity of twin pregnancy. Several algorithms including biomarkers of angiogenesis in prediction of 
PE in twin pregnancy are available and seem promising, however more large prospective surveys are necessary to assess 
their usefulness in general clinic use.
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INTRODUCTION
Pre-eclampsia is one of the most serious pregnancy 
complications and occurs in approximately 5% of pregnant 
women [1]. According to the Polish Society of Gynecolo-
gists and Obstetricians, pre-eclampsia (PE) is diagnosed in 
case of hypertension which develops after 20 gestational 
weeks accompanied by proteinuria, acute kidney injury, 
hepatic, hematological or neurological complications, or 
fetal risks [2]. Currently, two hypotheses are linked to PE 
etiology: impaired implantation and abnormalities in the 
immune response of the pregnant woman to the implanted 
fertilized egg. Abnormal trophoblast implantation and the 
lack of adequate conversion of the spiral arteries of the 
uterus lead to trophoblast cell hypoxia and the resultant 
reperfusion, which is associated with the formation of free 
radicals and disrupted secretion of angiogenic factors. They 
include placental growth factor (PlGF), one of the elements 
of the family of endothelial growth factors (VEGF) which are 
responsible for angiogenesis. It is secreted in high concen-
trations by the cyto- and syncytiotrophoblast [3]. Its level 
increases with the development of gestation reaching the 
peak around 30 weeks of gestation. Subsequently, the secre-
tion decreases [3]. Soluble fms-like tyrosine kinase-1 (sFlt-1) 
is a molecule which binds circulating vascular growth fac-
tors (PlGF and VEGF) making them biologically inactive. 
Intragestationally, sFlt-1 concentration remains constant 
until approximately 32 weeks, and then it increases [4, 5]. 
Endoglin (Eng) is a transmembrane glycoprotein which 
serves as a TGF beta receptor. Its high expression occurs 
on the surface of decidual cells and the trophoblast [6]. 
Eng participates in nitrogen oxide metabolism. Therefore, it 
also influences angiogenesis and vascular function. The con-
centration of soluble Eng (sEng) correlates with the occur-
rence of hypertension and proteinuria during pregnancy [7]. 
Reduced PlGF concentrations and increased sFlt-1 and sEng, 
which have anti-angiogenic properties, contribute to the 
development of PE in singleton pregnancies.
In patients with twin gestations PE is more common 
than in single gestations [8]. According to Laine et al. [9], 
a cohort study conducted in over 16 thousand of twin ges-
tations showed that the risk of PE was over 3-fold higher in 
twin than single pregnancies. The reason for such a correla-
tion may be linked to the secretion of different amounts of 
pro- and anti-angiogenic factors by the placenta in single and 
multiple pregnancies and the difference between placental 
weight. Published literature includes reports on the correla-
tion between PE occurrence and the type of chorionicity of 
a twin gestation. However, published data are contradictory. 
Most studies demonstrated that PE was more common in pa-
tients with dichorionic rather than monochorionic gestations 
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[10–12]. However, other authors reported a higher frequency 
of PE in women with a monochorionic pregnancy [13] or the 
lack of correlation with chorionicity [14–16]. Moreover, the 
etiology of the above-mentioned correlations is unknown. 
It may be due to the differences in the secretion of pro- and 
anti-angiogenic factors by the placenta in mono- and di-
chorionic gestations. The present paper includes a review of 
available literature concerning PlGF, sFlt-1 and sEng secretion 
in mono- and dichorionic twin gestations.   
DIFFERENCES IN THE SECRETION  
OF ANGIOGENIC FACTORS IN SINGLE  
AND TWIN GESTATIONS
Placental weight is markedly different between single 
and twin gestations. According to Bdolah et al. [17] the av-
erage weight of the placenta is 716 g in a single gestation, 
while in a twin gestation it is considerably larger and weighs 
on average 1246 g (p < 0.001). The biomarkers of angiogen-
esis are released by trophoblast cells, so it may be assumed 
that their concentration in the sera of patients with single 
and twin pregnancies are different.  The majority of studies 
published worldwide showed that those hypothetical dif-
ferences are present. Faupel-Badger et al. [18] investigated 
the concentration of sFlt-1 in the sera of patients with single 
and twin pregnancies at 10, 18, 26, and 35 weeks of gestation 
and perinatally. They demonstrated that sFlt-1 concentra-
tions were higher in twin pregnancies compared to single 
pregnancies in each of the analyzed time intervals. Similar 
results were also published by other authors [17–24]. Obser-
vations regarding PlGF secretion in single and twin gesta-
tions are also consistent. Numerous authors reported higher 
PlGF concentrations in women with twin gestations com-
pared to single gestations [19–26]. Faupel-Badger et al. [18] 
observed higher PlGF concentrations in twin gestations 
than in single gestations in each analyzed interval of gesta-
tions except week 35 in which the correlation was inverse. 
Sanchez et al. analyzed the levels of biomarkers of angiogen-
esis in single and multiple gestations over the 1st trimester. 
They reported higher sFlt-1 and PlGF concentrations in twin 
pregnancies [20]. Maynard et al. [24] analyzed a group of 
patients with a high risk of PE development between 22 and 
36 gestational weeks. In the study group sFlt-1 concentra-
tions were higher and increased more rapidly in twin gesta-
tions than in single gestations, while PlGF concentrations 
were higher than in single gestations, but they decreased 
more rapidly. Studies concerning sEng presented contradic-
tory results. Three studies have been published so far. They 
compared sEng concentrations in the sera of patients with 
single and twin pregnancies. According to Jeyabalan et al. 
and Faupel-Badger et al. sEng was secreted in higher 
amounts in patients with twin pregnancies, while Sánchez 
et al. did not observe such differences [18–20].  
DIFFERENCES IN THE SECRETION  
OF ANGIOGENIC FACTORS IN MONO-  
AN DICHORIONIC TWIN GESTATIONS
No unambiguous data have been published in profes-
sional literature available worldwide to confirm whether 
PlGF, sFlt-1 and sEng secretion was dependent on the chorio-
nicity in twin gestations. Cowans and Spencer [27] analyzed 
PlGF concentrations in 440 dichorionic, 116 monochorionic 
and in 607 single pregnancies in the 1st trimester. Higher 
PlGF concentrations were noted in 41% of dichorionic gesta-
tions and in 16% of monochorionic gestations compared to 
single gestations. Francisco et al. [26] also reported a higher 
PlGF concentration in the serum of women with dichorionic 
twin gestations compared to monochorionic and single 
gestations in the 1st trimester. Faupel-Badger et al. [18] 
determined sFlt-1 and sEng concentrations in subsequent 
measurements during pregnancy. The authors noted higher 
sFlt-1 and sEng concentrations in monochorionic compared 
to dichorionic gestations, also after correlations were made 
according to gestational age. Conversely, contradictory re-
sults have also been published in professional literature 
worldwide. Sanchez et al. [20] and Svirsky et al. [25] reported 
no differences in the secretion of PlGF, sFlt-1 and sEng be-
tween mono- an dichorionic gestations. 
DIFFERENCES IN THE SECRETION OF 
ANGIOGENIC FACTORS IN TWIN GESTATIONS 
COMPLICATED AND UNCOMPLICATED WITH PE 
In 2016 Tsiakkas et al. [28] reported on the distribution 
of PlGF concentrations at weeks 12, 22, 32 and 36 of single 
gestations complicated and uncomplicated with PE. Having 
examined over 40 thousand pregnant women the authors 
concluded that lower PlGF concentrations were strongly 
correlated with PE development. In the same year, the results 
of PROGNOSIS study were published. It was a prospective 
observational cohort study conducted in over 1000 women 
whose sFlt-1:PlGF ratio was determined between 24 and 
36 weeks of gestation in order to assess its usefulness in 
the prediction of PE occurrence. The study showed a high 
negative predictive value of sFlt-1:PlGF ratio < 38 for PE 
development over the following 7 days (99.3%) and a 66% 
sensitivity for the ratio > 38 for the development of PE over 
the following four weeks [29]. Those findings facilitated 
the development of sensitive methods of PE prediction in 
single pregnancies. 
However, professional literature available worldwide 
includes no such explicit results as regards the correlation 
of the biomarkers of angiogenesis with the risk of PE in twin 
gestations. Most published reports showed that sFlt-1 con-
centrations in twin gestations complicated by PE were 
higher than in gestations uncomplicated by PE [19–22, 30]. 
Moreover, lower PlGF concentrations were observed in 
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gestations with PE [19, 21, 22, 25, 26, 31, 32]. The differences 
between both biomarkers were confirmed in all trimesters of 
gestation. According to Dröge et al. an increased sFlt-1:PlGF 
ratio is associated with a higher risk of PE in twin gesta-
tions. The authors reported higher sFlt-1 and lower PlGF 
concentrations in twin pregnancies with PE. sFlt-1:PlGF ratio 
was as high in twin gestations with PE as in single gesta-
tions complicated by PE [22]. Independent teams of Powers 
et al. and Metz et al. demonstrated an analogous correla-
tion between sFlt-1+sEng:PlGF index and the development 
of PE in twin gestations [19, 31]. Jeyabalan et al. [19] also 
noted significantly higher sEng concentrations between 
31 and 35 gestational weeks in women who developed PE. 
Dröge et al. also analyzed the correlation between PE sever-
ity and the concentrations of angiogenesis biomarkers in 
twin gestations. The authors observed a significantly higher 
sFlt-1 and lower PlGF concentration both in mild and severe 
pre-eclampsia compared to uncomplicated gestations [22]. 
The analysis of professional literature also showed con-
tradictory results which revealed no differences between the 
concentrations of angiogenesis biomarkers in twin gestations 
complicated and uncomplicated with PE. According to Sanchez 
et al. [20] sFlt-1 concentrations were similar in the sera of wom-
en with PE and uncomplicated ones. Furthermore, Saleh et 
al. [23] noted no significant differences regarding PlGF and 
sFlt-1 secretion in pregnancies complicated and uncomplicated 
by PE. However, their study included only 21 women.
Basing on the observed differences, a number of authors 
assessed the usefulness of those biomarkers in the models of 
PE prediction in twin gestations. Rana et al. [33] developed 
an algorithm to estimate the risk of PE-related complications 
in twin gestations for the following 2 weeks. The algorithm 
is based on gestational age, the highest measurement of 
blood pressure, the presence of proteinuria and the value 
of sFlt-1:PlGF ratio. The area under the curve (AUC) reached 
0.93 with the use of all the above elements. In 86% of women 
whose sFlt-1:PlGF ratio reached or exceeded 85, the delivery 
occurred within two weeks following the measurement. 
However, various authors disagreed as regards the cut-off 
value of sFlt-1:PlGF ratio for twin gestations. According to 
Dröge et al. [22] the optimal cut-off value for PE prediction 
in twin gestations was ≥ 53. Saleh et al. [23] verified the 
usefulness of ≤ 38 ratio to rule out short-term risk of PE de-
velopment in twin gestations. However, 5 out of 13 women 
with the ratio of > 38  and 4 out of 8 women with the ratio 
of ≤ 38 developed PE. The authors concluded that the value 
of the ratio of ≤ 38 was not useful in twin gestations. Predic-
tive algorithms of the 1st trimester of pregnancy seem to 
be more effective. Boucoiran et al. [21] demonstrated a high 
effectiveness of PE prediction in the 1st trimester of a twin 
gestation with the use of PlGF concentrations (AUC 0.81, 
10% of false positive results). Francisco et al. developed a PE 
predictive model comprising maternal factors, mean blood 
pressure, the pulsatility index of uterine arteries and PlGF 
concentration in the 1st trimester of pregnancy. The detec-
tion rate of PE resulting in delivery prior to 32 weeks of 
gestation was 100% (AUC 0.94), while before 37 weeks of 
gestation it was 99% (AUC 0.82). However, the percentage 
of false positive results was high (75%) [26]. The algorithm 
is available online: https://fetalmedicine.org. 
The presented options of algorithms to predict PE seem 
promising. However, it is still impossible to assess their clini-
cal usefulness. It is necessary to conduct a large prospective 
study and include such factors as twin gestation chorionicity 
or PE severity. The inclusion of such factors is necessary to 
improve the algorithms before they are recommended for 
general use. The development of an effective algorithm 
would contribute to the improvement of the perinatal care 
of women with twin gestations and the improvement of the 
perinatal results of twin gestations. 
SUMMARY
Twin pregnancy is one of the risk factors for develop-
ment of PE. Soluble fms-like tyrosine kinase-1, placental 
growth factor, and soluble endoglin are biomarkers involved 
in the process of angiogenesis with a proven role in the 
pathogenesis of PE. Most of available data suggest their con-
centrations differ between singleton and twin gestation and 
between monochorionic and dichorionic twin pregnancy. 
Several algorithms including biomarkers of angiogenesis in 
prediction of PE in twin pregnancy are available and seem 
promising, however more large prospective surveys are 
necessary to assess their usefulness in general clinic use.
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